R1VT34 Stock Overview
Provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Revvity, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.20 |
| 52 Week High | US$26.28 |
| 52 Week Low | US$18.06 |
| Beta | 1.03 |
| 1 Month Change | -6.22% |
| 3 Month Change | 3.29% |
| 1 Year Change | n/a |
| 3 Year Change | -29.70% |
| 5 Year Change | 59.33% |
| Change since IPO | 56.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| R1VT34 | BR Life Sciences | BR Market | |
|---|---|---|---|
| 7D | -11.7% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how R1VT34 performed against the BR Life Sciences industry.
Return vs Market: Insufficient data to determine how R1VT34 performed against the BR Market.
Price Volatility
| R1VT34 volatility | |
|---|---|
| R1VT34 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in BR Market | 0% |
| 10% least volatile stocks in BR Market | 0% |
Stable Share Price: R1VT34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine R1VT34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1937 | 11,000 | Prahlad Singh | www.revvity.com |
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Revvity, Inc. Fundamentals Summary
| R1VT34 fundamental statistics | |
|---|---|
| Market cap | R$77.87b |
| Earnings (TTM) | R$1.61b |
| Revenue (TTM) | R$15.70b |
48.3x
P/E Ratio5.0x
P/S RatioIs R1VT34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R1VT34 income statement (TTM) | |
|---|---|
| Revenue | US$2.76b |
| Cost of Revenue | US$1.22b |
| Gross Profit | US$1.54b |
| Other Expenses | US$1.25b |
| Earnings | US$283.07m |
Last Reported Earnings
Dec 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.33 |
| Gross Margin | 55.81% |
| Net Profit Margin | 10.27% |
| Debt/Equity Ratio | 41.1% |
How did R1VT34 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield12%
Payout RatioDoes R1VT34 pay a reliable dividends?
See R1VT34 dividend history and benchmarks| Revvity dividend dates | |
|---|---|
| Ex Dividend Date | Apr 17 2025 |
| Dividend Pay Date | May 15 2025 |
| Days until Ex dividend | 59 days |
| Days until Dividend pay date | 87 days |
Does R1VT34 pay a reliable dividends?
See R1VT34 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 03:53 |
| End of Day Share Price | 2025/02/13 00:00 |
| Earnings | 2024/12/29 |
| Annual Earnings | 2024/12/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revvity, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Charles Butler | Barclays |